Technical Data
V2110-15T
Vascular Endothelial Growth Factor, Recombinant, Human (VEGF, Vascular Endothelial Growth Factor A, VEGFA, VEGF-A, MGC70609, MVCD1, Vascular Permeability Factor, VPF)
2ug
|
Technical Data |
|
V2110-15T |
Vascular Endothelial Growth Factor, Recombinant, Human (VEGF, Vascular Endothelial Growth Factor A, VEGFA, VEGF-A, MGC70609, MVCD1, Vascular Permeability Factor, VPF) |
2ug |
| Growth Factors, Cytokines | Storage: -20°CShipping: Blue Ice |
|
Source: Recombinant corresponding to 165aa of human Vascular Endothelial Growth Factor expressed in E.coli is a double, non-glycosylated, polypeptide chain. Molecular Weight: ~38.2kD Biological Activity: The biological activity is determined by the dose-dependent stimulation of the proliferation of human umbilical vein endothelial cells (HUVEC) using a concentration range of 1.0-8.0 nug/ml. Dimmers and Aggregates: 1% (SDS-PAGE) Protein Content: Protein quantitation was carried out by two independent methods:1. UV spectroscopy at 280nm using the absorbency value of 0.2875 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENEcomputer analysis program of protein sequences (IntelliGenetics). 2. Analysis by RP-HPLC, using a calibrated solution of VEGF as a Reference Standard. Storage and Stability: Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile ddH2O, HSA or BSA. Aliquot to avoid repeated freezing and thawing. Store at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. Molecular Weight: ~38.2kD |
Purity: ~98% (RP-HPLC, Anion-exchange FPLC, SDS-PAGE) Endotoxin: 0.1ng/ug (IEU/ug) Concentration: ~1mg/ml Form: Supplied as a lyophilized powder. No preservative added. Reconstitute with sterile dH2O, 0.1% HSA or BSA to 0.1mg/ml. Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. |
|
1. VEGF as a therapeutic target in cancer. Oncology 2005;69 Suppl 3:11-6. 2. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005;69 Suppl 3:4-10. 3. Introduction. Critical role of anti-angiogenesis and VEGF inhibition in colorectal cancer. Oncology 2005;69 Suppl 3:1-3. 4. Biological effects of a software-controlled voltage pulse generator (PhyBack PBK-2C) on the release of vascular endothelial growth factor (VEGF). In Vivo 2005 Nov-Dec;19(6):949-58. 5. Facilitation of a structural transition in the polypurine/polypyrimidine tract within the proximal promoter region of the human VEGF gene by the presence of potassium and G-quadruplex-interactive agents. Nucleic Acids Res 2005 Oct 20; 33(18):6070-80. 6. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005 Oct;8(4):299-309.
|
||